-
Roussel Uclaf S.A. was a
French pharmaceutical company and one of
several predecessor companies of today's Sanofi. It was the
second largest French pharmaceutical...
-
mifepristone for
personal use in 1989, a
decision supported by
Roussel Uclaf. In 1994,
Roussel Uclaf gave the U.S. drug
rights to the Po****tion
Council in exchange...
- He
later obtained an MBA at HEC Paris. In
April 1986, he
joined Roussel Uclaf (formerly France's
second largest pharmaceutical company,
until bought by...
-
Julien Gaston Roussel, who was
President and
General Manager of the
Roussel Uclaf Laboratoires Pharmaceutiques, and his wife,
Francine Grinda,
daughter of...
- Roxithromycin's half-life is 12 hours.
French pharmaceutical company Roussel Uclaf first marketed roxithromycin in 1987.
Fischer J,
Ganellin CR (2006). Analogue-based...
-
Predecessors Sanofi-Synthélabo
Aventis Hoechst Rhône-Poulenc C****ella
Roussel Uclaf Marion Merrell Dow CEOs
Chris Viehbacher Olivier Brandicourt Main products...
-
antiandrogen (NSAA)
which was
initially developed in the 1980s by
Roussel Uclaf, the
French pharmaceutical company from
which it
received its name. It was...
- The drug
appears to have been an
early development project of
Roussel Uclaf, a
French pharmaceutical company, and by the
early 1970s, it was
being sold...
-
itself was
formed from the 1995
merger of
Hoechst AG with C****ella,
Roussel Uclaf, and
Marion Merrell Dow.
Hoechst AG, the
majority partner at the time in...
-
Reliant (????–2007)
Renovo (1998–2011) Rhône-Poulenc (1928–1999)
Roussel Uclaf (1911–1997) S. E. M****engill (1898–2011)
Salix (1989–2015)
Sanofi Pasteur...
